GlassScriptPhysician profile
Joan S Purcell
NPI 1023045978
$86,608.22
in general payments reported to CMS, 2019-2025
27 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 97% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,457 · 2020: $228 · 2021: $30K · 2022: $20K · 2023: $28K · 2024: $1,029 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $2,406 · Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,850.00 |
| Travel and Lodging | $2,405.72 |
| Food and Beverage | $2,278.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $83,640.57 | 2019-2025 | Bexsero, Penmenvy, Fluarix Quadrivalent |
| Alexion Pharmaceuticals, INC. | $757.44 | 2021-2022 | |
| Corium, LLC | $417.11 | 2022-2025 | Azstarys |
| Dexcom, INC. | $346.02 | 2022-2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $164.89 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $163.41 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $136.11 | 2020-2022 | |
| Tris Pharma INC | $123.95 | 2020-2023 | Dyanavel Xr |
| Qol Medical, LLC | $121.85 | 2024 | Sucraid |
| Merck Sharp & Dohme LLC | $117.74 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $103.53 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $78.72 | 2023-2025 | Ycanth |
| Supernus Pharmaceuticals, INC. | $78.25 | 2021-2023 | Qelbree |
| Sanofi Pasteur INC. | $55.39 | 2023 | |
| Neos Therapeutics, LP | $55.27 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $40.30 | 2019-2022 | |
| Genentech USA, INC. | $26.84 | 2020-2021 | |
| Adlon Therapeutics L.P. | $25.97 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.92 | 2025 | Keveyis |
| Nestle Healthcare Nutrition INC. | $21.47 | 2021 | |
| Alk-Abello, INC | $20.90 | 2024 | Odactra, Grastek |
| Sobi, INC | $18.73 | 2021 | |
| Companion Medical, INC. | $15.70 | 2019 | |
| Lnhc, INC | $15.15 | 2025 | Zelsuvmi |
| Tolmar, INC. | $14.16 | 2024 | |
| Ascendis Pharma Endocrinology INC | $13.92 | 2023 | |
| Shire North American Group INC | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.